Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 25;15(6):e0235076.
doi: 10.1371/journal.pone.0235076. eCollection 2020.

Biologic excipients: Importance of clinical awareness of inactive ingredients

Yelena Ionova  1 , Leslie Wilson  2
Affiliations
Review

Biologic excipients: Importance of clinical awareness of inactive ingredients

Yelena Ionova et al. PLoS One. .

Abstract

Due to the complexity and fragility of biological drug products, several challenges exist in their formulation development. Excipients are added to increase product stability, maintain tonicity, and facilitate drug delivery. The potential implications of these additive substances merit clinical consideration. We assessed the safety risk of excipients on the basis of their type and variability through an assessment framework, which quantifies excipient complexity in 230 biological formulations, and identifies excipient-related adverse events through published case reports. A biologic on average contained 4.45 excipients, half of that found in oral medications. The frequency distribution was heavily skewed towards the most commonly occurring excipients: water (40.4%), sodium chloride (38.3%), polysorbate 80 (28.7%), sucrose (24.4%), and mannitol (20.9%), with 44.4% of formulations not listing the concentration of the most commonly occurring inactive ingredients. A literature search revealed only 17 case reports of excipient-related adverse events, suggesting the need for more clarity for clinicians on the safety of chemical additives. These cases included injection site reactions, anaphylaxis, hyperglycemia, and acute renal failure. With the expansion of the biopharmaceutical market, it is important to consider the safety data of biologic excipients, so that therapy can be tailored appropriately for a specific patient.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Data extraction methodology.
Fig 2
Fig 2. Distribution of inactive ingredients in biologic formulations.
Fig 3
Fig 3. Frequency of inactive ingredients in biologic formulations expressed as a Gini coefficient.
See this image and copyright information in PMC

References

    1. U.S. Food and Drug Administration. Inactive Ingredient Field Descriptions. Available from: https://www.fda.gov/drugs/informationondrugs/ucm075230.htm. Last updated 15 May 2015.
    1. Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS One 2017; 12(7):e0181748 10.1371/journal.pone.0181748 - DOI - PMC - PubMed
    1. U.S. Food and Drug Administration. Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for delivery at the Brookings Institution on the release of the FDA’s Biosimilars Action Plan. July 2018.
    1. U.S. Food and Drug Administration. Biosimilars Action Plan: Balancing Innovation and Competition. July 2018. Available from: https://www.fda.gov/media/114574/download
    1. Reker D, Blum SM, Steiger C, Anger KE, Sommer JM, Fanikos J, et al. “Inactive” ingredients in oral medications. Sci Transl Med 2019; 11(483): eaau6753 10.1126/scitranslmed.aau6753 - DOI - PMC - PubMed

Publication types

MeSH terms